

CERTIFICATE OF ANALYSIS – TECHNICAL DATA SHEET

Product name C4c, Human, clone 99-72-18

Catalog number HM2399-100UG

Lot number - Expiry date -

Volume 1 ml Amount 100 μg

Formulation 0.2 μm filtered in PBS+0.1%BSA+0.02%NaN3 Concentration 100 μg/ml

Host Species Mouse IgG2b, kappa Conjugate None

Endotoxin N.A. **Purification** Protein G

Storage 4°C

Application notes

	IHC-F	IHC-P	IF	FC	FS	IA	IP	W
Reference #						1	1	1
Yes						•	•	•
No								
N.D.	•	•	•	•	•			

N.D.= Not Determined; IHC = Immuno histochemistry; F = Frozen sections; P = Paraffin sections; IF = Immuno Fluorescence; FC = Flow Cytometry; FS = Functional Studies; IA = Immuno Assays; IP = Immuno Precipitation; W = Western blot

Dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50.

- IA: HM2399 can be used as capture or detection antibody (Ref.1).
- W: the monoclonal antibody is useful for Western blotting under non-reduced conditions. The expected band size for non-reduced samples is 146 kDa.

General Information

Description

Antibody clone 99-72-18 recognizes human complement fragment C4c. C4c reflects the degree of complement activation via the classical and lectin pathway. The complement system plays important roles in both innate and adaptive immune response and can produce an inflammatory and protective reaction to challenges from pathogens before an adaptive response can occur. It consists of a complex family of proteins and receptors which are found in the circulation, in tissues and other body-fluids. There are three pathways of complement activation. The classical pathway is initiated by Immune complexes; the lectin pathway by surface bound lectins; and the AP by all the surfaces that are not specifically protected against it. The C3 and C5 convertases are enzymatic complexes that initiate and amplify the activity of the complement pathways and ultimately generate the cytolytic MAC.

Initiation of the CP & LP leads to activation of C4 and C2. The arising anaphylotoxins activate the immune system. The larger fragments interact with cell surfaces, receptors, immune complexes or other complement proteins. This way among others the C3 convertase (C4b2b) is formed. The complement system is involved in a number of diseases like transplantation rejection, kidney diseases, AMD and inflammatory diseases. Therefor complement fragments serve as biomarkers for many of these diseases. C4 is a glycoprotein consisting of an alpha chain, beta chain and gamma chain. Activation yields C4a and C4b. C4b is inactivated by factor I in the presence of C4bp resulting in C4c and C4d. Thus soluble C4c is a measure of complement activation.

References

 Pilely, K. et al; A specific assay for quantification of human C4c by use of an anti-C4c monoclonal antibody. J Immunol method 2014, 405: 87

Version: 06-2020

Storage&stability

Product should be stored at 4°C. Under recommended storage conditions, product is stable for at least one year.

Precautions

For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result from the use or derivation of this product.

We hereby certify that the above-stated information is correct and that this product has been successfully tested by the Quality Control Department. This product was released for sale according to the existing specifications. This document has been produced electronically and is valid without a signature.

Approved by Manager of QC Brenda Teunissen

Date 16/04/2021

Do you have any questions or comments regarding this product? Please contact us via support@hycultbiotech.com.